ATE380884T1 - Verwendung von mirtazapin zur verbesserung der behandlung von menschen mit starken depressionen, welche träger des gens für apolipoprotein e4 sind. - Google Patents
Verwendung von mirtazapin zur verbesserung der behandlung von menschen mit starken depressionen, welche träger des gens für apolipoprotein e4 sind.Info
- Publication number
- ATE380884T1 ATE380884T1 AT02704147T AT02704147T ATE380884T1 AT E380884 T1 ATE380884 T1 AT E380884T1 AT 02704147 T AT02704147 T AT 02704147T AT 02704147 T AT02704147 T AT 02704147T AT E380884 T1 ATE380884 T1 AT E380884T1
- Authority
- AT
- Austria
- Prior art keywords
- apolipoprotein
- gene
- patient
- mirtazapine
- major depression
- Prior art date
Links
- 108010060159 Apolipoprotein E4 Proteins 0.000 title abstract 4
- RONZAEMNMFQXRA-UHFFFAOYSA-N mirtazapine Chemical compound C1C2=CC=CN=C2N2CCN(C)CC2C2=CC=CC=C21 RONZAEMNMFQXRA-UHFFFAOYSA-N 0.000 title abstract 3
- 229960001785 mirtazapine Drugs 0.000 title abstract 3
- 208000024714 major depressive disease Diseases 0.000 abstract 5
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 230000004797 therapeutic response Effects 0.000 abstract 2
- 101710095339 Apolipoprotein E Proteins 0.000 abstract 1
- 102100029470 Apolipoprotein E Human genes 0.000 abstract 1
- 239000000935 antidepressant agent Substances 0.000 abstract 1
- 230000005540 biological transmission Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 238000003205 genotyping method Methods 0.000 abstract 1
- 230000002474 noradrenergic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Seasonings (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/780,512 US6399310B1 (en) | 2001-02-12 | 2001-02-12 | Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4 |
| US10/010,087 US20030105082A1 (en) | 2001-12-03 | 2001-12-03 | Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE380884T1 true ATE380884T1 (de) | 2007-12-15 |
Family
ID=26680764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02704147T ATE380884T1 (de) | 2001-02-12 | 2002-02-12 | Verwendung von mirtazapin zur verbesserung der behandlung von menschen mit starken depressionen, welche träger des gens für apolipoprotein e4 sind. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20040106124A1 (de) |
| EP (1) | EP1442133B1 (de) |
| JP (1) | JP2004532190A (de) |
| AT (1) | ATE380884T1 (de) |
| AU (1) | AU2002237847A1 (de) |
| DE (1) | DE60224078T2 (de) |
| ES (1) | ES2296893T3 (de) |
| WO (1) | WO2002064735A2 (de) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007092380A2 (en) * | 2006-02-06 | 2007-08-16 | Berkeley Heartlab, Inc. | Apolipoprotein e genotyping and accompanying internet-based health management system |
| WO2016138357A1 (en) | 2015-02-27 | 2016-09-01 | Kindred Biosciences, Inc. | Stimulation of appetite, management of weight loss, and treatment of anorexia in dogs and cats |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL189199C (nl) * | 1975-04-05 | 1993-02-01 | Akzo Nv | Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten. |
| US4515792A (en) * | 1982-09-30 | 1985-05-07 | Ciba-Geigy Corporation | Tetracyclic heterocycles and antidepressant compositions thereof |
| US5178878A (en) * | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
| DK0431663T3 (da) * | 1989-12-06 | 1994-03-07 | Akzo Nobel Nv | Stabiliserende opløsninger af psykotrope midler |
| JP3265577B2 (ja) * | 1992-10-13 | 2002-03-11 | デューク・ユニバーシティ | アポリポ蛋白ｅの４型イソ型の測定法 |
| GB9408465D0 (en) * | 1994-04-27 | 1994-06-22 | Univ Mcgill | Apolipoprotein e polymorphism & treatment of alzheimer's disease |
| US6022683A (en) * | 1996-12-16 | 2000-02-08 | Nova Molecular Inc. | Methods for assessing the prognosis of a patient with a neurodegenerative disease |
| IL121076A (en) * | 1996-06-19 | 2000-10-31 | Akzo Nobel Nv | Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors |
| US6117855A (en) * | 1996-10-07 | 2000-09-12 | Merck Sharp & Dohme Ltd. | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent |
| ZA982368B (en) * | 1997-03-27 | 1998-09-23 | Akzo Nobel Nv | New therapeutic combinations |
| ZA985765B (en) * | 1997-07-02 | 1999-08-04 | Merck & Co Inc | Polymorphic form of a tachykinin receptor antagonist. |
| CA2297005A1 (en) * | 1997-09-12 | 1999-03-25 | Anthony David Smith | Method for determining propensity for developing late-onset alzheimer's disease |
| US5985936A (en) * | 1997-12-18 | 1999-11-16 | Forbes Medi-Tech, Inc. | Method of preventing and delaying onset of Alzheimer's disease and composition therefor |
| US6063573A (en) * | 1998-01-27 | 2000-05-16 | Clinical Micro Sensors, Inc. | Cycling probe technology using electron transfer detection |
| DE69913116T2 (de) * | 1998-04-02 | 2004-06-03 | Akzo Nobel N.V. | Orale flüssige lösung enthaltend das antidepressivum mirtazapine |
-
2002
- 2002-02-12 DE DE60224078T patent/DE60224078T2/de not_active Expired - Fee Related
- 2002-02-12 AU AU2002237847A patent/AU2002237847A1/en not_active Abandoned
- 2002-02-12 WO PCT/US2002/001248 patent/WO2002064735A2/en not_active Ceased
- 2002-02-12 ES ES02704147T patent/ES2296893T3/es not_active Expired - Lifetime
- 2002-02-12 JP JP2002565050A patent/JP2004532190A/ja not_active Withdrawn
- 2002-02-12 EP EP02704147A patent/EP1442133B1/de not_active Expired - Lifetime
- 2002-02-12 US US10/467,768 patent/US20040106124A1/en not_active Abandoned
- 2002-02-12 AT AT02704147T patent/ATE380884T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2004532190A (ja) | 2004-10-21 |
| DE60224078T2 (de) | 2008-12-04 |
| EP1442133B1 (de) | 2007-12-12 |
| EP1442133A4 (de) | 2005-01-05 |
| US20040106124A1 (en) | 2004-06-03 |
| WO2002064735A2 (en) | 2002-08-22 |
| ES2296893T3 (es) | 2008-05-01 |
| EP1442133A2 (de) | 2004-08-04 |
| WO2002064735A3 (en) | 2004-05-13 |
| DE60224078D1 (de) | 2008-01-24 |
| AU2002237847A1 (en) | 2002-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE399553T1 (de) | Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen | |
| ATE348808T1 (de) | Azacyclische verbindungen zur verwendung in der behandlung von mit serotonin verwandten krankheiten | |
| MY169308A (en) | Treatment of tnf? related disorders | |
| ATE144420T1 (de) | Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen | |
| SG146653A1 (en) | Methods and reagents for the treatment of immunoinflammatory disorders | |
| DE60027732D1 (de) | Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems | |
| CY1107640T1 (el) | Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη | |
| UA82828C2 (en) | The use of enantiomeric pure escitalopram for treatment of depression | |
| DE60320770D1 (de) | Verfahren zur verabreichung von buprenorphin zur behandlung von depression | |
| ATE447426T1 (de) | Elektromagnetische stimulation bei patienten mit osteoporose | |
| JO3446B1 (ar) | طريقة لمعالجة الأرق الأولي | |
| MXPA00010254A (es) | Tratamiento de disfuncion sexual en ciertos grupos de pacientes. | |
| ATE380884T1 (de) | Verwendung von mirtazapin zur verbesserung der behandlung von menschen mit starken depressionen, welche träger des gens für apolipoprotein e4 sind. | |
| DE602004016547D1 (de) | 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen | |
| ATE544453T1 (de) | Kombinationstherapien mit l-fmau zur behandlung von hepatitis-b-virus-infektionen | |
| DE69930419D1 (de) | Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie | |
| TW200501958A (en) | A therapeutic agent for treating a behavioral disorder | |
| DE69733321D1 (de) | Olanzapine zur behandlung von drogenmissbrauch | |
| ATE288263T1 (de) | Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis) | |
| DE60013636D1 (de) | Verfahren zur behandlung endzünlicher darmerkrankungen durch verwendung von choleratoxin untereinheit b | |
| ATE237616T1 (de) | Verwendung von (1r,4s)-4-(6-amino-9h-purin-9-yl)- 2-cyclopenten-1-methanol in hbv | |
| DE602004015321D1 (de) | 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen | |
| DE69830811D1 (de) | Verwendung von Oxazolidinonderivaten zur Behandlung von Psoriasis | |
| DE60213968D1 (de) | Blutgerinnungsfaktor xiii zur behandlung von plättchenfunktionsstörungen | |
| MXPA05010216A (es) | Uso de ritonavir para el tratamiento de hiperbilirrubinemia no conjugada. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |